A headline about a peptide policy can sound like a new drug approval. Ask what actually changed: an approval, an ingredient rule, or an agency's proposed approach to enforcement. These are different questions. Keep the name and form of the proposed compound (such as an injection) beside the dated policy before asking what it means for a price or a care offer.
What the HHS draft describes
HHS, the federal health department, announced this compounding draft on October 30, 2026. The notice calls it nonbinding: it does not create a legal right to compound. HHS described a plan to take no action against compounding that meets the draft's conditions. The substances named are epitalon, BPC-157, semax, TB-500, KPV, and MOTS-c. The draft concerns a single ingredient and a prescription for a named person. It covers doctors and state-licensed pharmacies working under section 503A. Mixtures of ingredients are outside its scope. So are section 503B outsourcing facilities, businesses registered with FDA that make medicines in batches for hospitals and clinics.
- Under this proposed approach, the agency would choose not to act when the stated conditions are met. That choice would not be FDA approval.
- The tables attached to the draft limit the exact ingredients and the ways they may be given. Ask whether the proposed ingredient and way of giving it match those tables; a peptide name alone does not settle that question.
- Ask the prescriber to name the condition in the draft that applies to the proposed compound. Keep that explanation with the written care plan.
Source notes
The source below supports the point above, within its stated limits.
Federal Register · HHS draft noticeHHS · draft conditions and ingredient tablesWhat a committee account does not establish
The check dated November 3, 2026 found an official HHS account saying the July 2026 advisory committee favored six of the seven peptides discussed. That account is separate from FDA meeting minutes. The committee's advice does not itself amend the ingredient list. None of the six named in the HHS policy appeared on FDA's official 503A bulks list in that check. Listing requires formal agency rulemaking; a favorable committee account is not the completed step.
- Keep the committee account, the draft policy, and FDA approval separate when reading an offer. They describe different events.
- Withdrawing a request to add an ingredient does not mean FDA approved it or allowed its use in compounding. FDA's page still listed safety concerns alongside the withdrawn requests; its content was current as of April 22, 2026.
- Ask which document supports a claim that compounding is allowed. A dated document is easier to check than a broad claim that the rules have changed.
Source notes
The source below supports the point above, within its stated limits.
HHS · draft conditions and ingredient tablesFDA · ingredient-list processFDA · substance entries and concernsKeep Indiana requirements in the picture
The state sourcing rules checked November 3, 2026 took effect July 1, 2026. They bar ingredients sold for laboratory research outside an approved study, and ingredients meant for animal use. They also call for records of origin, identity, and quality. The HHS draft leaves those state rules in place. Meeting the sourcing rules does not itself make a given drug lawful to compound under federal law. Ask how the actual proposed drug fits both sets of rules. A broad claim about the draft leaves that open.
- Ask who prepares the drug and how the pharmacy's Indiana standing can be checked. Use the name in the state record.
- Ask the clinician (doctor, physician assistant, or nurse practitioner) to explain why this preparation is proposed for your case. Keep that answer separate from the advertised price.
- If the explanation depends on a newer document, request its title and date. Leave an unresolved policy question open rather than filling it with an assumption.
- For a quote that rests on this draft, ask the service to explain what it would do if the key terms changed. Get the payment answer alongside the policy explanation so a question about the rules does not quietly become an assumed long-term supply promise.
Source notes
Use the state search for a current record of the named person or facility.
Indiana · enacted sourcing requirementsFederal Register · draft policy scope